Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-TLX250 PET/CT in Metastatic Triple Negative Breast Cancer
NCT04758780Phase 2Completed
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 89Zr-DFO-girentuximab in triple-negative breast cancer (TNBC), sponsored by Institut Cancérologique de l'Ouest. Started Sep 2021; status: completed.
02
Drugs
89Zr-DFO-girentuximab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04758780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04758780.